ORIGINAL ARTICLE
Prognostic value of p53 protein expression in giant cell tumor of bone
Submission date: 2015-04-09
Final revision date: 2015-08-19
Acceptance date: 2015-08-25
Publication date: 2016-02-05
Pol J Pathol 2015;66(4):389-396
KEYWORDS
TOPICS
ABSTRACT
Giant cell tumor of bone (GCTB) is a benign tumor with a tendency for local recurrence. GCTB may cause lung metastases, and secondary malignant GCTB is rare. Its histological appearance does not predict local aggressiveness and/or the metastatic potential of the tumor. We aimed to investigate the prognostic value of the Ki-67 proliferative index and p53 protein expression in GCTB in predicting local recurrence, lung metastasis, and malignant transformation. We retrospectively reviewed 42 cases of GCTB. The p53 expression was positive in 20 cases. We used 10% as a cut-off value for p53 expression. In 10 cases, there were local recurrences. Lung metastases were found in three cases and malignant transformation was found in one case with classical GCTB located in the sacrum three years following diagnosis. The Ki-67 index was higher in cases with recurrence, but this difference was not statistically significant. Of the recurrent cases, two had no p53 staining while eight had moderate-to-strong staining. The staining was usually weakly positive in the non-recurrent cases. In conclusion, we believe that p53 may be used as a marker for the biological behavior of GCTB.
REFERENCES (30)
1.
Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. World Health Organization Classification of Tumours of Soft Tissue and Bone. IARC, Lyon 2013; 321-324.
2.
Folpe AL, Inwards CY. Bone and Soft Tissue Pathology. Saunders Elsevier, Philadelphia 2010; 401-407.
3.
Jaffe HL, Linchenstein L, Portis R. Giant cell tumor of bone. Arch Pathol 1940; 30: 993-1031.
4.
Alberghini M, Kliskey K, Krenacs T, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010; 456: 97-103.
5.
Gupta R, Seethalakshmi V, Jambhekar NA, et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008; 12: 239-248.
6.
Jiang N, Qin CH, Tan CX, et al. A retrospective analysis of 140 patients with giant cell tumor in the extremity: A multicenter study based on four hospitals in South China. Cancer Epidemiol 2013; 37: 294-299.
7.
Errani C, Ruggieri P, Asenzio MAN, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010; 36: 1-7.
8.
Liu J, Yang H, Sun R, et al. Retrospective analysis of patients with rare-site and metastatic giant cell tumor. Chin J Cancer Res 2013; 25: 585-592.
9.
Zang K, Zhou M, Chen H, et al. Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis. Clin Transl Oncol 2015;17: 570-575.
10.
Chan CM, Adler Z, Reith JD, et al. Risk factors for pulmonary metastases from giant cell tumor of bone. J Bone Joint Surg Am 2015; 97: 420-428.
11.
Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol 2014; 12: 261.
12.
Okubo T, Saito T, Mitomi H, et al. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Arch 2013; 463: 67-77.
13.
Oda Y, Sakamoto A, Saito T, et al. Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology 2001; 39: 629-637.
14.
Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134: 969-978.
15.
Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1985; 204: 9-36.
16.
Saito T, Mitomi H, Suehara Y, et al. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up. Pathol Res Pract 2011; 207: 664-669.
17.
Saito T, Mitomi H, Izumi H, et al. A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up. Hum Pathol 2011; 42: 727-733.
18.
Balke M, Ahrens H, Streitbuerger A, et al. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol 2009; 135: 149-158.
19.
Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone. Clin Orthop Relat Res 2011; 469: 591-599.
20.
Campanacci M, Baldini N, Boriani S, et al. Giant cell tumor of bone. J Bone Joint Surg Am 1987; 69: 106-114.
21.
Heijden L, Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones, A retrospective study of 93 patients. Acta Orthop 2012; 83: 401-405.
22.
Yanagisawa M, Okada K, Tajino T, et al. A clinicopathological study of giant cell tumor of small bones. Ups J Med Sci 2011; 116: 265-268.
23.
Miller IJ, Blank A, Yin SM, et al. A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol 2010; 5: 62-68.
24.
Papanastassiou I, Ioannou M, Papagelopoulos PJ, et al. p53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 2010; 33: 307.
25.
Ismail FW, Shamsudin AM, Wan Z, et al. Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone. J Exp Clin Cancer Res 2010; 29: 25.
26.
Rousseau MA, Luca AH, Lazennec JY, et al. Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study. Virchows Arch 2004; 445: 79-82.
27.
Kauzman A, Li SQ, Bradley G, et al. Cyclin alterations in giant cell tumor of bone. Mod Pathol 2003; 16: 210-218.
28.
Wu Y, Hsiu J, Lou Y, et al. p53 protein accumulation and genetic alterations in human giant cell tumors of bone (osteoclastomas). Int J Oncol 1997; 10: 1087-1092.
29.
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003; 97: 2520-2529.
30.
Gong L, Liu W, Sun X, et al. Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch 2012; 460: 327-334.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
